New research indicates that patients who stop using popular slimming jabs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Research printed in a major health publication demonstrates that while overweight people can lose substantial amounts of their body weight while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these treatments should be informed of the potential of rapid rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.
This pace of regain means a reversion to starting mass within about 18 months.
Analyzing Treatments
The research, which examined dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods.
The team emphasize that individuals who lose weight through lifestyle changes alone usually have a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Nutrition scientists believe the mechanism of the drugs accounts for the amplified weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' means hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Disease?
Medical guidelines advise the injections for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, due to the high risk of relapse, the therapy should be considered life-long.
This opinion is supported by pharmaceutical companies, who say that the findings "highlight the persistent character of excess weight," comparing it to managing conditions like hypertension.
Patient Experiences
Users who have discontinued the medication describe a sudden resurgence of appetite.
"It felt as if a trigger that goes on and I was suddenly starving," described an individual.
The struggle is compounded if patients have not adopted lasting lifestyle or habit modifications during treatment.
Growing Adoption
Figures indicate that a significant number of adults in the UK have used these injections in the past year, with interest continuing to grow.
- Use is higher among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and maintained weight loss hinges on ongoing behavioural changes.
